Cardinal Health Inc. ($CAH) Stock Forecast: Up 7.3% Today

What is Cardinal Health Inc.?

Cardinal Health (NYSE: CAH) operates as a major healthcare distributor catering to healthcare providers and manufacturers globally. The company's role is vital in ensuring the availability of pharmaceutical and medical products for patient care support.

Why is Cardinal Health Inc. going up?

CAH stock is up 7.3% on Feb 5, 2026 14:56

• Today, Cardinal Health (CAH) witnessed a notable uptrend following the announcement of exceptional Q4 CY2025 results that outperformed market predictions.
• The company's strong financial showing was fueled by a substantial increase in revenue, surpassing analyst forecasts by a significant margin.
• Cardinal Health adjusted its full-year EPS guidance upwards, indicating optimism in its strategic efforts and the strong industry momentum in healthcare distribution.
• The upsurge in demand for specialty drugs and the company's foray into high-profit markets were key drivers in the positive outlook and the heightened profitability projections, further instilling investor confidence in Cardinal Health's future prospects.

CAH Price Chart

CAH Technical Analysis

CAH News

McKesson Corporation (NYSE:MCK) Q3 2026 Earnings Call Transcript

McKesson Corporation reported strong Q3 Fiscal 2026 results, exceeding earnings expectations with an EPS of $9.34. The company saw double-digit revenue and adjusted EPS growth, driven by oncology, biopharma services, and North American distribution. McKesson raised its full-year EPS guidance to $38.80 to $39.20, reflecting continued momentum and successful strategic initiatives including acquisitions and technology investments in AI and automation.

https://www.insidermonkey.com/blog/mckesson-corporation-nysemck-q3-2026-earnings-call-transcript-1689423/

Cardinal Health (NYSE:CAH) Exceeds Q4 CY2025 Expectations

Cardinal Health (NYSE:CAH) announced Q4 CY2025 results that surpassed market expectations, with an 18.8% year-on-year revenue increase to $65.63 billion and non-GAAP profit exceeding analyst estimates by 11.2%. The company also raised its full-year Adjusted EPS guidance to $10.25 at the midpoint. This strong performance was driven by double-digit segment profit growth across all operating segments, indicating a solid financial quarter for the healthcare distributor.

https://finviz.com/news/301086/cardinal-health-nyse-cah-exceeds-q4-cy2025-expectations

Cardinal Health boosts annual profit forecast banking on surging demand for specialty drugs

Cardinal Health has raised its annual profit forecast after exceeding Wall Street's quarterly estimates, attributing the strong performance to robust demand for specialty medicines and growth across its segments. The company's shares increased by over 3% in premarket trading following the announcement. This positive outlook is driven by the industry-wide surge in demand for high-margin drugs treating complex conditions and strategic expansions into the specialty medicines market.

https://www.reuters.com/business/healthcare-pharmaceuticals/cardinal-health-boosts-annual-profit-forecast-banking-surging-demand-specialty-2026-02-05/

Cardinal: Fiscal Q2 Earnings Snapshot

Cardinal Health Inc. (CAH) reported fiscal second-quarter earnings of $467 million, or $1.97 per share, with adjusted earnings of $2.63 per share, surpassing Wall Street expectations of $2.39 per share. The prescription drug distributor also exceeded revenue forecasts, posting $65.63 billion. The company anticipates full-year earnings between $10.15 and $10.35 per share, and its stock has shown significant growth over the past year.

https://www.kens5.com/article/syndication/associatedpress/cardinal-fiscal-q2-earnings-snapshot/616-645b9825-a0de-48e1-b89d-7632d5608c1e

Cardinal Health Lifts Outlook After Posting Higher Profit

Cardinal Health has increased its full-year outlook after reporting higher profits and revenue in its fiscal second quarter. The company now anticipates adjusted earnings between $10.15 and $10.35 per share, surpassing both its previous guidance and analyst expectations. This positive revision reflects strong recent performance and continued momentum.

https://www.wsj.com/business/earnings/cardinal-health-lifts-outlook-after-posting-higher-profit-a12eb285?gaa_at=eafs&gaa_n=AWEtsqdgLUtq_DsrUUpREf4cUk0-w-93FI9taBQ9ebpKitmRXShzFc1BIels&gaa_ts=69849683&gaa_sig=jwzUpoeEFNxprng_xt8ASksfKa0M8cKtRoswICjAJyT7HxGjjIWRULYobRCsdEyWAVuMU4Vd07GTzpgM9oCg4g%3D%3D

Trending Today

Cigna Corporation ($CI) Stock Forecast: Up 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 3.6% Today

Capital One Financial Corporation ($COF) Stock Forecast: Down 4.5% Today

Goldman Sachs Group Inc. (The) ($GS) Stock Forecast: Down 4.5% Today

Eli Lilly and Company ($LLY) Stock Forecast: Down 5.2% Today

Roku Inc. ($ROKU) Stock Forecast: Down 8.5% Today

Alcoa Corporation ($AA) Stock Forecast: Down 7.5% Today

Huntington Ingalls Industries Inc. ($HII) Stock Forecast: Down 9.0% Today

HP Inc. ($HPQ) Stock Forecast: Down 5.3% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 7.4% Today

Cardinal Health Inc. Price History

05.00.2026 - CAH Stock was up 1.0%

• The strategic shift towards specialty pharmaceutical distribution and healthcare services by Cardinal Health is positively impacting its growth trajectory.
• The overall bullish sentiment in the pharmaceutical industry, as evidenced by the projected growth of the Palliative Care Market, is likely contributing to CAH's upward movement.
• Analysts lowering price targets for competitors like Cencora (COR) while maintaining a Neutral rating may be diverting investor attention towards Cardinal Health, driving its stock price higher.
• The recognition of Cardinal Health as a stable long-term investment due to its essential role in the healthcare supply chain and consistent demand for medications is attracting investors seeking steady growth opportunities.

02.11.2025 - CAH Stock was down 3.0%

• The bearish movement in Cardinal Health's stock today could be attributed to various factors:
• Despite the company's increased operating earnings, the recent revenue dip might have raised concerns among investors about its growth prospects.
• The acquisition announcement and year-end results reporting might have not met market expectations, leading to a negative sentiment towards the stock.
• The overall market sentiment towards healthcare stocks or specific developments within the healthcare sector could have influenced the bearish movement in CAH's stock price.
• Investors might be reevaluating Cardinal Health's financial stability and growth potential in comparison to other highlighted stocks with strong interest coverage ratios.
• The focus on financial metrics like the Price-to-Earnings ratio and valuation scores in discussions about other companies could have also shifted investor attention away from Cardinal Health, impacting its stock performance negatively.

13.00.2026 - CAH Stock was up 5.2%

• Following an upward trend, Cardinal Health's stock witnessed a surge subsequent to the company's revision of its fiscal-year guidance and its forecast of specialty revenue surpassing $50 billion for 2026.
• The optimistic projections for 2026, fueled by successful strategic moves like alterations in Medicare Drug Prices and alliances with Publix Super Markets, played a significant role in driving the stock's upward trajectory.
• Launches such as the ContinuCare™ Pathway program for diabetes supply management, coupled with strong performance across operational sectors, underscored the company's substantial strategic advancement.
• In essence, Cardinal Health's favorable forecasts and strategic endeavors have bolstered investors' confidence, thereby propelling the bullish trend in the stock market.

08.00.2026 - CAH Stock was down 3.0%

• The recent decline in CAH stock price could be linked to profit-taking by investors following a previous increase in value.
• Although Cardinal Health delivered impressive Q3 earnings that exceeded analyst expectations, market sentiment or profit-related concerns may have driven the stock lower.
• An increased investment by Robeco Institutional Asset Management B.V. initially inspired confidence in the stock, but prevailing market conditions may have overshadowed this development.
• Investor focus on the strong performance and growth potential of McKesson in the healthcare sector may have diverted attention from Cardinal Health, impacting its stock performance unfavorably.

03.09.2025 - CAH Stock was down 3.7%

• Cardinal Health (CAH) may have faced a downward trend due to its underperformance relative to other medical stocks like Arcutis Biotherapeutics (ARQT).
• The subdued performance of CAH in the healthcare industry this year might be linked to the market's negative movement.
• Investors could be turning their attention towards more promising opportunities in the medical field, resulting in a sell-off of CAH shares.
• Contrasting with ARQT's strong showing could have revealed weaknesses in CAH's finances or growth prospects, prompting investors to review their positions and contributing to the bearish trend.

12.07.2025 - CAH Stock was down 7.3%

• There has been bullish options activity indicating positive sentiment from investors, although this did not result in a positive stock movement.
• The company exceeded earnings estimates and raised EPS guidance for 2026, leading to a stock drop potentially linked to concerns about the expiration of the OptumRx contract and its impact on Pharmaceutical segment sales.
• The upcoming release of Q4 earnings may have caused stock price volatility as investors reacted to forecast changes and dividend income strategies.
• A comparison with Adaptive Biotechnologies in the medical sector suggests that market dynamics and company-specific factors could have influenced Cardinal Health's bearish performance despite positive developments.

12.07.2025 - CAH Stock was down 12.2%

• The bearish movement in CAH stock could be attributed to investors' concerns about the upcoming earnings report falling short of expectations.
• Discussion about earning $500 a month from CAH stock might have raised unrealistic expectations among investors, leading to disappointment when the stock did not perform as anticipated.
• A comparison with Adaptive Biotechnologies (ADPT) might have highlighted stronger performance in the medical sector by ADPT, causing some investors to shift their focus away from CAH.
• Overall, the bearish movement in CAH could be a result of a combination of profit-taking, cautious investor sentiment ahead of the earnings report, and comparative underperformance within the sector.

05.01.2026 - CAH Stock was up 7.3%

• Today, Cardinal Health (CAH) witnessed a notable uptrend following the announcement of exceptional Q4 CY2025 results that outperformed market predictions.
• The company's strong financial showing was fueled by a substantial increase in revenue, surpassing analyst forecasts by a significant margin.
• Cardinal Health adjusted its full-year EPS guidance upwards, indicating optimism in its strategic efforts and the strong industry momentum in healthcare distribution.
• The upsurge in demand for specialty drugs and the company's foray into high-profit markets were key drivers in the positive outlook and the heightened profitability projections, further instilling investor confidence in Cardinal Health's future prospects.

04.01.2026 - CAH Stock was down 5.0%

• Cardinal Health revised its FY25 earnings forecast upwards, anticipating notable growth in EPS over the next three years, which should typically have a positive effect on the stock.
• Allianz Asset Management GmbH decreased its ownership in Cardinal Health by 30%, potentially indicating investor uncertainty or profit-taking, which could have contributed to the recent market decline.
• Despite the encouraging earnings forecast and solid segment performance, the market's response towards Cardinal Health appears to have been more influenced by the significant reduction in ownership by a major investor, leading to the recent downturn.
• Various factors such as the overall healthcare sector's performance and general market trends may have also impacted the recent bearish movement of Cardinal Health's stock.

30.09.2025 - CAH Stock was up 17.6%

• Cardinal Health (CAH) saw a solid uptrend today, with its stock price rising by +1.72%.
• The positive market sentiment towards CAH is driven by expectations of robust Q1 earnings, especially in its Pharmaceutical and Specialty units.
• CAH has consistently outperformed the market over the past 5 years, with an average annual return of 27.8%, attracting investors seeking stable returns in the healthcare sector.
• The favorable expectations for CAH's financial performance and its strong position in the healthcare industry have fueled the uptick in its stock price today.

30.09.2025 - CAH Stock was up 17.4%

• Cardinal Health (CAH) experienced a strong bullish movement today, with its stock price increasing by +1.72%.
• The positive market movement can be attributed to the expectation of double-digit revenue growth in Q1 FY26, primarily driven by the Pharmaceutical and Specialty units.
• Additionally, the company's consistent outperformance in the market over the past 5 years, with an average annual return of 27.8%, has likely contributed to investor confidence and buying interest in CAH shares.
• Overall, the market seems optimistic about Cardinal Health's future prospects, supported by strong financial performance and growth potential in key business segments.

30.09.2025 - CAH Stock was up 13.0%

• The stock of Cardinal Health saw a notable increase following the positive announcement of its first-quarter 2026 earnings. Adjusted earnings outperformed expectations, and sales witnessed a substantial year-over-year growth.
• Cardinal Health's successful performance in Q1 and the upgraded 2026 EPS forecast point towards a widespread expansion and growing profitability across all sectors, fostering investor confidence.
• Investor optimism towards Cardinal Health has been influenced by its consistent market outperformance in the last 5 years, indicating attractive returns for stakeholders.
• Anticipated double-digit revenue growth in the first quarter of fiscal year 2026, especially in the Pharmaceutical and Specialty units, has further heightened investor confidence in the company's future prospects, encouraging a bullish trend in the stock price.